**Core tip:** Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are slow-growing cancers that arise from diffuse endocrine cells in the gastrointestinal tract and pancreas. An increased emphasis has been placed on health-related quality of life assessment in clinical studies, using reliable and validated patient-reported outcome instruments. Long-term therapeutic options provide symptomatic relief for patients with GEP-NETs, and can slow down or stabilise disease progression, but are not curative. Thus, understanding the impact of the long-term treatment options is particularly important. The aim of this study was to perform a systematic review to assess health-related quality of life focusing on patients with inoperable metastatic GEP-NETs undergoing different treatments in order to uncover areas for future research.

INTRODUCTION
============

Gastroenteropancreatic tumours (GEP-NETs) account for 2% of all gastrointestinal malignancies, with a United Kingdom age-standardised incidence rate of 8.6/100000/year\[[@B1]\]. GEP-NETs tend to be slow-growing cancers arising from diffuse endocrine cells in the gastrointestinal tract (GI-NETs) or pancreas (P-NETs). GEP-NETs are categorised as "functioning" or "non-functioning". Functioning tumours cause symptoms due to the hypersecretion of peptides and hormones\[[@B2],[@B3]\], whilst non-functioning tumours have no hormone-related clinical features. Specific symptoms vary by primary tumour location\[[@B4],[@B5]\]. Around 3 in 10 patients with GI-NET develop symptoms of diarrhoea, abdominal pain and flushing due to increased serotonin production\[[@B6]\], known as carcinoid syndrome (CS). P-NETs can produce a variety of hormones, the most common of which are insulin and gastrin. Other abnormal hormone production associated with GEP-NETs include glucagon, vasoactive intestinal peptide, adrenocorticotropic hormone, somatostatin, and parathyroid hormone-related protein\[[@B7]\].

Surgery is the only curative treatment for GEP-NETs and can be performed when tumours are localised and resectable. The majority of GEP-NET patients, however, are diagnosed with metastatic disease requiring systemic treatment\[[@B8],[@B9]\], including chemotherapy, biological therapies, and peptide receptor radionuclide therapy (PRRT)\[[@B10]\]. These long-term therapeutic options provide symptomatic relief, and can slow down or stabilise disease progression, but are not curative. The 5-year survival rate for patients with metastatic GI-NETs is approximately 75% and the 5-year survival rate for patient with metastatic P-NETs is \> 60%, whilst the prevalence of GEP-NETs has been on the rise in the recent decades\[[@B2],[@B11]\]. For instance, the median overall time of survival from the date of diagnosis of distant metastatic disease was reported to be 103 mo (8.5 years) in patients with metastatic midgut GI-NETs\[[@B12]\]. It is therefore vital to assess the patient's health-related quality of life (HRQoL) in general and related to the disease whilst taking treatments which can have a marked impact on well-being.

In oncology, an increased emphasis has been placed on HRQoL assessment as a secondary endpoint in clinical studies, using reliable and thoroughly validated patient-reported outcome (PRO) instruments for which the minimal important difference for improvement/worsening has been defined\[[@B13]-[@B17]\]. High-quality information on HRQoL serves a variety of purposes such as the development of targeted interventions, informed decision making about treatment options and allocation of healthcare resources\[[@B18]\]. Indeed, the United States Food and Drug Administration and European Medicines Agency have published guidance on the use of PRO measures in oncology studies emphasising the value of patient perspective when evaluating medicinal products\[[@B19],[@B20]\].

To date, systematic assessments of HRQoL in patients with GEP-NETs have been performed to a limited extent. In the past, where the literature was systematically evaluated, the review focused on the methodological quality of the identified studies\[[@B18]\]. To our knowledge, there has been no systematic literature review published to provide a comprehensive overview of the different treatment options and associated impact on the patients' HRQoL. The aim of our study was to perform a systematic review to assess HRQoL focusing on patients with inoperable metastatic GEP-NETs undergoing different treatments in order to uncover areas for future research.

MATERIALS AND METHODS
=====================

Search strategy and study selection
-----------------------------------

This systematic review adheres to the established international guidelines for conducting systematic reviews, such as those provided by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses report (PRISMA Statement\[[@B21]\]), and the Cochrane Handbook for Systematic Reviews of Interventions\[[@B22]\]. Methods of analysis and inclusion criteria were defined in advance and outlined in a designated protocol.

An extensive search of MEDLINE, Embase and the Cochrane library was performed by an experienced information specialist to identify relevant studies. We examined articles published in English between January 1985 and November 2019. The protocol outlined the electronic search strategy in full; searches were supplemented by manual searches of relevant review journals.

After de-duplication, article titles and abstracts were independently reviewed by two analysts, with discrepancies resolved *via* discussion with a third reviewer. Full-text articles were then obtained for records that met the inclusion criteria to re-evaluate eligibility.

Eligibility criteria
--------------------

Eligibility for this systematic review was defined according to the PICOS\[[@B21]\]. Participants were adult patients (≥ 18 years) with inoperable GEP-NETs. Outcome measures included HRQoL, PROs, utility estimates, validity, and minimally important difference. The study design incorporated studies reporting utility estimates and HRQoL data, including economic evaluations, observational studies, and relevant randomised control trials. Cross-sectional studies were included, as they can provide useful HRQoL data at a specific point in time, although not providing longitudinal changes due to treatment over time. Studies were also required to report at least one relevant outcome for ≥ 15 patients. There were no limits defined in terms of intervention or comparator PICOS elements.

Articles were excluded if patients were diagnosed with neuroendocrine tumours that did not originate in the gastrointestinal tract or the pancreas, and when the HRQoL data for patients with GEP-NETs were not separated by sub-analysis (*e.g*., the population included patients with lung and/or thyroid neuroendocrine tumours). Studies indexed as case reports, case series, editorials and letters, conference abstracts, systematic reviews and non-human studies were also excluded. Finally, studies where the treatment applied did not target the malignancies specifically, such as psychotherapeutic interventions, were excluded.

Data extraction
---------------

A dedicated data extraction sheet was devised to capture all relevant data, including publication details, study design, country, intervention(s), comparator(s), eligibility, population description (including any specific sub-groups), sample size, age (average and range), sex ratio, tumour location, description of HRQoL measure (including valuation technique, method of elicitation, timepoints, follow-up duration, response rates), utility tool assessment (including disease state, timepoint, average utility) and HRQoL assessment (including scale domain where relevant, timepoint, average score, data spread). Disagreements were resolved by discussion between the two reviewers, with third reviewer involvement as required.

Quality assessment
------------------

The quality and relevance of HRQoL studies were assessed based on the key criteria described by Papaioannou et al\[[@B23]\] and Brazier et al\[[@B24]\], where applicable. Papers reporting insufficient information to assess study methods and populate the data extraction sheet were considered lower quality and were excluded on this basis.

RESULTS
=======

Identified literature
---------------------

A total of 42 studies published between 1985 and 2019 met the inclusion criteria of this study, of which 32 were found electronically and 10 were found by handsearching the reference lists of relevant articles (Figure [1](#F1){ref-type="fig"}). Of these studies, 6 can be classed as cross-sectional studies. There was a combined total of 3552 participants in the 42 studies, excluding healthy participants used for comparisons and the duplicate patients taken from the same data, with study sample sizes ranging from 17 to 253 patients. The heterogeneous nature of the different study populations was evident; the percentage of female participants ranged between 30%-60%, whilst average age ranged from 53.8 to 67.0 years (Table [1](#T1){ref-type="table"}). In terms of disease location, 8 studies focused on GI-NET patients only and 6 studies focused on P-NET patients; the remaining studies were either a combination of both populations or did not report the specific disease location.

###### 

Extracted literature

  **Ref**.                                              **Intervention**                                                                                                                         **Comparator(s)**                                                                                                                            **Study design, "Open" Label / "Blinded" / "Double blinded"**              **Total sample size**   **Patient sub-group**                                                        **Pt sub-group sample size**                              **Sex (% female)**                                                                                                                                                                                                                 **Average age (yr)**                                                                                                                    **Mean/median**   **Total GI-NET, %**   **P-NET, %**   **Functioning /Non-functioning, "function"**                                                                                                                                                                                    **Additional information about disease[1](#T1FN1){ref-type="table-fn"}: "Stage (TNM)" "progressive" "stable", ("advanced" "metastatic/metastases" "spread") ("grow" "grade" "differentiated")**
  ----------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------- ----------------------- ---------------------------------------------------------------------------- --------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------- ----------------- --------------------- -------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Zandee et al\[[@B58]\], 2019                          ^177^Lu-DOTATATE                                                                                                                         NA                                                                                                                                           Retrospective study                                                        34                      NA                                                                           NA                                                        50                                                                                                                                                                                                                                 59                                                                                                                                      Mean              NA                    100            Functioning (100%)                                                                                                                                                                                                              Grade 1 or 2 tumours with metastases (stage IV). Metastatic disease sites: Liver (97%), bone (21%), lung (6%)
  Ramage et al\[[@B54]\], 2019                          Everolimus                                                                                                                               NA                                                                                                                                           Phase IV, open                                                             48                      All Patients                                                                 46                                                        30                                                                                                                                                                                                                                 64.3                                                                                                                                    Median            NR                    100            NR                                                                                                                                                                                                                              Advanced and/or metastatic, well-differentiated, grade 1 and 2
  Continuing treatment at month 6                       30                                                                                                                                       NR                                                                                                                                           NR                                                                         NR                      NR                                                                           NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Ballal et al\[[@B8]\], 2019                           ^225^Ac-DOTATATE                                                                                                                         NA                                                                                                                                           Prospective study, open                                                    21                      NA                                                                           NA                                                        57                                                                                                                                                                                                                                 54                                                                                                                                      Median            38                    57             NR                                                                                                                                                                                                                              Metastatic GEP-NETs with stable disease after completing ^177^Lu-PRRT (57%) or progressive disease on ^177^Lu-PRRT (43%). Grades 1 (*n* = 9), 2 (*n* = 11), and 3 (*n* = 1). Metastatic disease sites: Liver (86%), lymph node (71%), bone (33%)
  Marinova et al\[[@B61]\], 2019                        ^177^Lu-DOTATATE                                                                                                                         NA                                                                                                                                           Retrospective study                                                        70                      NA                                                                           NA                                                        44.3                                                                                                                                                                                                                               64.2                                                                                                                                    Mean              100                   NR             Functioning (83%), non-functioning (17%)                                                                                                                                                                                        Metastatic. Grade 1 (50%), grade 2 (35.7%), unknown (14.3%). Morphological or clinical progression prior to 1^st^ cycle PRRT (78.6%)
  Rinke et al\[[@B16]\], 2019                           Long-acting octreotide                                                                                                                   Placebo (sodium chloride)                                                                                                                    Clinical trial (RCT), Phase IIIb trial, double blind, placebo controlled   85                      Long-acting octreotide                                                       42                                                        49.4                                                                                                                                                                                                                               62.4                                                                                                                                    Mean              NR                    NR             Functioning (39%), non-functioning (61%)                                                                                                                                                                                        Metastatic, liver metastases (86%)
  Placebo                                               43                                                                                                                                                                                                                                                                                    60.3                                                                       Mean                    NR                                                                           NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  NA                                                    NA                                                                                                                                                                                                                                                                                    NR                                                                         NA                      NR                                                                           NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Martini et al\[[@B59]\], 2018                         DOTATATE or ^90^Y-DOTATOC                                                                                                                General population norms                                                                                                                     Retrospective study                                                        61                      Small intestine NET patients                                                 37                                                        40.5                                                                                                                                                                                                                               62.8                                                                                                                                    Mean              100                   0              NR                                                                                                                                                                                                                              No brain metastases; otherwise not defined
  P-NET patients                                        24                                                                                                                                       37.5                                                                                                                                         61.0                                                                       Mean                    0                                                                            100                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  Lewis et al\[[@B3]\], 2018                            Not defined                                                                                                                              Patients with CS *vs* patients without CS                                                                                                    Prospective study                                                          50                      Without CS (CS)                                                              25                                                        48.0                                                                                                                                                                                                                               62.0                                                                                                                                    Median            60.0                  40.0           NR                                                                                                                                                                                                                              Advanced, well-differentiated, with liver metastases
  With CS (CS)                                          25                                                                                                                                       36.0                                                                                                                                         67.0                                                                       Median                  96.0                                                                         4.0                                                       NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  Strosberg et al\[[@B17]\], 2018                       ^177^Lu-DOTATATE                                                                                                                         High-dose octreotide                                                                                                                         Clinical trial (RCT), phase III, open                                      231                     ^177^Lu-DOTATATE                                                             117                                                       NR                                                                                                                                                                                                                                 NR                                                                                                                                      NR                100                   NR             NR                                                                                                                                                                                                                              Advanced, progressive, low- or intermediate-grade
  octreotide LAR                                        114                                                                                                                                      NR                                                                                                                                           NR                                                                         NR                      100                                                                          NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Karppinen et al\[[@B46]\], 2018                       NA                                                                                                                                       Control population                                                                                                                           Cross-sectional                                                            134                     Impaired excretion                                                           87                                                        55                                                                                                                                                                                                                                 66.8                                                                                                                                    Mean              100                   NR             Flushing (31%), diarrhoea (63%)                                                                                                                                                                                                 Locally advanced or metastatic disease (91%), grade 1 (54.1%), grade 2 (45.9%)
  Cella et al\[[@B44]\], 2018                           Telotristat ethyl                                                                                                                        Placebo                                                                                                                                      Clinical trial (RCT), phase III trial, double blind                        135                     NA                                                                           135                                                       48.1                                                                                                                                                                                                                               63.6                                                                                                                                    Mean              NR                    NR             NR                                                                                                                                                                                                                              Well-differentiated, metastatic NETs and CS inadequately controlled by somatostatin analogues (for ≥ 3 mo)
  Durable responders (DR)                               48                                                                                                                                       52.1                                                                                                                                         63.4                                                                       Mean                    NR                                                                           NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Non-durable responders (DR)                           87                                                                                                                                       46                                                                                                                                           63.6                                                                       Mean                    NR                                                                           NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Meng et al\[[@B28]\], 2017                            Somatostatin analogue lanreotide                                                                                                         Placebo                                                                                                                                      Clinical trial (RCT), phase III trial, double blind                        204                     Lanreotide                                                                   101                                                       48                                                                                                                                                                                                                                 62.1                                                                                                                                    Mean              NR                    NR             Non-functioning                                                                                                                                                                                                                 Advanced, well-differentiated or moderately differentiated, somatostatin receptor-positive NETs of grade 1 or 2
  Placebo                                               103                                                                                                                                                                                                                                                                                                                                                                                      NR                                                                           NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Overall                                               204                                                                                                                                                                                                                                                                                                                                                                                      NR                                                                           NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Vinik et al\[[@B35]\], 2016                           Sunitinib plus best supportive care                                                                                                      Placebo plus best supportive care                                                                                                            Clinical trial (RCT), phase III trial, double blind                        171                     NA                                                                           NA                                                        NR                                                                                                                                                                                                                                 NR                                                                                                                                      NR                NA                    100            NR                                                                                                                                                                                                                              Advanced and/or metastatic, pathologically confirmed, well-differentiated P-NETs with disease progression as assessed by RECIST
  Haugland et al\[[@B9]\], 2016                         None                                                                                                                                     None                                                                                                                                         Cross-sectional                                                            196                     None                                                                         NA                                                        50.5                                                                                                                                                                                                                               65.0                                                                                                                                    Mean              100.0                 0.0            NR                                                                                                                                                                                                                              NR
  Pavel et al\[[@B56]\], 2016                           Everolimus                                                                                                                               NA                                                                                                                                           Clinical trial, Phase IIIb, open, expanded access study                    246                     P-NET                                                                        126                                                       46                                                                                                                                                                                                                                 61                                                                                                                                      Median            NR                    100            Functioning (*n* = 38), non-functioning (*n* = 88)                                                                                                                                                                              Metastatic, well differentiated (*n* = 81), moderately differentiated (*n* = 26), poorly differentiated (*n* = 1), unknown (*n* = 16), missing (*n* = 2)
  Non P-NET                                             120                                                                                                                                      50.8                                                                                                                                         66                                                                         Median                  NR                                                                           0                                                         Functioning (*n* = 66), non-functioning (*n* = 55)                                                                                                                                                                                 Metastatic, well differentiated (*n* = 65), moderately differentiated (*n* = 34), poorly differentiated (*n* = 2), unknown (*n* = 19)                                                                                                                                                                                                                                                                                          
  Delpassand et al\[[@B66]\], 2014                      ^177^Lu-DOTATATE                                                                                                                         NA                                                                                                                                           Clinical trial, phase II, open                                             37                      Patients with available data participated in quality of life questionnaire   27                                                        56.8                                                                                                                                                                                                                               63.4                                                                                                                                    Mean              43.2                  37.8           NR                                                                                                                                                                                                                              Grade 1 and grade 2, disseminated, progressive, somatostatin receptor-positive. Multiple metastases in the liver: grade 2 (*n* = 4), grade 3 (*n* = 26), grade 4 (*n* = 7). Metastatic disease sites: Liver (*n* = 34), lymph nodes (*n* = 16), bone (*n* = 11), pancreas (*n* = 8), lung (*n* = 3)
  Ducreux et al\[[@B41]\], 2014                         Bevacizumab combined with 5-FU/ streptozocin (Mitry et al\[[@B40]\] 2014)                                                                Capecitabine plus bevacizumab                                                                                                                Clinical trial, phase II, open                                             34                      NA                                                                           NA                                                        35                                                                                                                                                                                                                                 55                                                                                                                                      Median            NR                    100            Functioning (*n* = 7): CS (*n* = 3), Zollinger--Ellison syndrome (*n* = 1), other (*n* = 3)                                                                                                                                     Progressive, metastatic disease. Metastatic disease sites: Liver (*n* = 33), lymph node (*n* = 14), peritoneum (*n* = 2), lung (*n* = 3), bone (*n* = 2), other (*n* = 2)
  Mitry et al\[[@B40]\], 2014                           Bevacizumab combined with 5-FU/ streptozocin (reported in a companion paper focusing on P-NET patients (Ducreux et al\[[@B41]\], 2014)   Capecitabine plus bevacizumab                                                                                                                Clinical trial, phase II, open                                             49                      NA                                                                           NA                                                        47                                                                                                                                                                                                                                 60                                                                                                                                      Median            100                   NA             NR                                                                                                                                                                                                                              Progressive, metastatic well-differentiated. Metastatic disease sites: Liver (*n* = 46), lymph node (*n* = 24), peritoneum (*n* = 23), lung (*n* = 7), bone (*n* = 7), other (*n* = 5)
  Meyer et al\[[@B42]\], 2014                           Capecitabine and streptozocin plus cisplatin (stratified)                                                                                Capecitabine and streptozocin (stratified)                                                                                                   Clinical trial (RCT), Phase II                                             86                      Capecitabine and streptozocin                                                44                                                        39                                                                                                                                                                                                                                 57                                                                                                                                      Median            21                    46.0           Functioning (*n* = 31; 36%)                                                                                                                                                                                                     Advanced and/or metastatic. Metastatic disease sites: Local/regional (*n* = 2), distant (*n* = 42), liver (included in distant; *n* = 41)
  Capecitabine and streptozocin plus cisplatin          42                                                                                                                                       45                                                                                                                                           59                                                                         Median                  19                                                                           50.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Yadegarfar et al\[[@B33]\], 2013                      Somatostatin analogues or interferon therapy (88 patients)                                                                               Peptide-receptor radiotherapy (102 patients), chemotherapy (23 patients), surgery (20 patients) or ablative/ other therapies (20 patients)   Phase IV, open                                                             253                     P-NET                                                                        70                                                        NR                                                                                                                                                                                                                                 NR                                                                                                                                      NR                NR                    NR             Functioning: Secreting 5-hydroxy-indoloacetic acid (*n* = 111), gastrin (*n* = 4), glucagon (*n* = 3), insulin (*n* = 5), vasoactive intestinal peptide (*n* = 1). Non-functioning (secreting only chromogranin-A; *n* = 124)   Any gut-primary with metastases, lung-primary with liver/abdominal metastases and pancreas with/without metastases
  Casciano et al\[[@B36]\], 2012                        Everolimus (Afinitor)                                                                                                                    Sunitinib (Sutent)                                                                                                                           Economic analysis of phase III studies                                     NA                      NA                                                                           NA                                                        NA                                                                                                                                                                                                                                 NA                                                                                                                                      NA                NA                    NA             NR                                                                                                                                                                                                                              Advanced, progressive
  Kvols et al\[[@B29]\], 2012                           Pasireotide                                                                                                                              Octreotide                                                                                                                                   Prospective study, phase II, open                                          44                      Pasireotide responders                                                       12 (Baseline), 12 (Month 1), 10 (Month 2), 11 (Month 3)   44                                                                                                                                                                                                                                 61                                                                                                                                      Mean              NR                    NR             NR                                                                                                                                                                                                                              Advanced, metastatic (symptoms refractory or resistant to octreotide LAR therapy). Metastatic disease sites: Liver (87%), lymph node (*n* = 16), peritoneum (*n* = 8), lung (*n* = 5), bone (*n* = 3), abdomen (*n* = 3), pleura (*n* = 3), retroperitoneal (*n* = 2), pancreas (*n* = 2), kidney (*n* = 1)
  Pasireotide non responders                            13 (Baseline), 13 (Month 1), 13 (Month 2), 13 (Month 3)                                                                                                                                                                                                                                                                                                                                  NR                                                                           NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Patients who discontinued treatment before 3 mo       19 (Baseline), 15 (Month 1), 8 (Month 2)                                                                                                                                                                                                                                                                                                                                                 NR                                                                           NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Raymond et al\[[@B34]\], 2011                         Sunitinib plus Best Supportive Care                                                                                                      Placebo plus Best Supportive Care                                                                                                            Clinical trial (RCT), phase III, double blind                              171                     sunitinib                                                                    86                                                        51                                                                                                                                                                                                                                 56                                                                                                                                      Median            NR                    100            Sunitinib Arm: Functioning: Gastrinoma (*n* = 9), glucagonoma (*n* = 3), insulinoma (*n* = 2), somatostatinoma (*n* = 1), other, multisecretory, or unknown (*n* = 10). Non-functioning (*n* = 42)                              Advanced and/or metastatic, progressive, well-differentiated
  Placebo                                               85                                                                                                                                       53                                                                                                                                           57                                                                         Median                  NR                                                                           100                                                       Placebo Arm: Functioning: Gastrinoma (*n* = 10), glucagonoma (*n* = 2), insulinoma (*n* = 2), vasoactive intestinal peptide--secreting tumour (*n* = 2), other, multisecretory, or unknown (*n* = 5). Non-functioning (*n* = 44)                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Pezzilli et al\[[@B49]\], 2009                        NA                                                                                                                                       NA                                                                                                                                           Prospective study                                                          51                      NA                                                                           NA                                                        58.8                                                                                                                                                                                                                               61                                                                                                                                      Mean              NR                    100            NR                                                                                                                                                                                                                              Advanced disease (lymph node involvement/liver metastases) (*n* = 22)
  Rinke et al\[[@B27]\], 2009                           Octreotide LAR                                                                                                                           Placebo                                                                                                                                      Clinical trial (RCT), phase IIIb, double blind                             85                      Octreotide LAR                                                               42                                                        52.4                                                                                                                                                                                                                               63.5                                                                                                                                    Median            100                   NR             Octreotide LAR arm: Functioning: CS (*n* = 17) 40.5%                                                                                                                                                                            Well-differentiated, metastatic. Metastatic disease sites: Liver (*n* = 73), regional lymph node involvement (*n* = 6)
  Placebo                                               43                                                                                                                                       46.5                                                                                                                                         61                                                                         Median                  100                                                                          NR                                                        Placebo arm: Functioning: CS (*n* = 16) 37.2%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Korse et al\[[@B30]\], 2009                           Long-acting sandostatin LAR                                                                                                              Short-acting Sandostatin                                                                                                                     Clinical trial, phase II                                                   39                      NA                                                                           NA                                                        51.3                                                                                                                                                                                                                               61                                                                                                                                      Mean              51.3                  NR             Functioning: CS (*n* = 39)                                                                                                                                                                                                      Metastatic: Liver metastases (*n* = 35)
  van der Horst-Schrivers et al\[[@B67]\] , 2009        NA                                                                                                                                       NA                                                                                                                                           Prospective study                                                          43                      NA                                                                           NA                                                        37.2                                                                                                                                                                                                                               60.6                                                                                                                                    Mean              NR                    NR             NR                                                                                                                                                                                                                              Metastatic midgut carcinoid tumours: Liver metastases (*n* = 37)
  Haugland et al\[[@B47]\], 2009                        NA                                                                                                                                       NA                                                                                                                                           Cross-sectional                                                            5341                    NET patients                                                                 189                                                       50                                                                                                                                                                                                                                 65                                                                                                                                      Mean              100                   NR             NR                                                                                                                                                                                                                              GI-NET patients (excluded radical surgery that may have been curative), otherwise undefined
  General population                                    5152                                                                                                                                     48.8                                                                                                                                         NR                                                                         NR                      NA                                                                           NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Larsson and Janson\[[@B50]\], 2008                    Erythropoietin                                                                                                                           None                                                                                                                                         Pilot study                                                                18                      None                                                                         NA                                                        50.0                                                                                                                                                                                                                               63.0                                                                                                                                    Mean              100                   NR             NR                                                                                                                                                                                                                              NR
  Kulke et al\[[@B55]\], 2008                           Sunitinib                                                                                                                                NA                                                                                                                                           Clinical trial, phase II, open                                             107                     NA                                                                           NA                                                        40.2                                                                                                                                                                                                                               Carcinoid tumour = 58, P-NET= 56                                                                                                        Median            37.3                  61.7           P-NET: Functioning: Gastrinoma *n* = 5 (7.6%), insulinoma *n* = 3 (4.5%), VIPoma *n* = 2 (3.0%), glucagonoma *n* = 4 (6.1%), other *n* = 5 (7.6%). Non-functioning *n* = 46 (69.7%)                                             Advanced carcinoid or P-NET
  Fröjd et al\[[@B37]\] , 2007                          Various included                                                                                                                         None                                                                                                                                         Longitudinal, prospective, comparative study                               59                      T1-T4 successful                                                             36                                                        47.0                                                                                                                                                                                                                               60.0                                                                                                                                    Mean              NR                    NR             NR                                                                                                                                                                                                                              Metastatic (70% metastatic at start; 78% metastatic at end)
  Davies et al\[[@B68]\], 2006                          NA                                                                                                                                       NA                                                                                                                                           Cross-sectional, open                                                      50                      Patients                                                                     35                                                        42.9                                                                                                                                                                                                                               60                                                                                                                                      Mean              NR                    NR             NR                                                                                                                                                                                                                              Metastatic
  Healthcare workers                                    15                                                                                                                                       NR                                                                                                                                           NR                                                                         NR                      NA                                                                           NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Frilling et al\[[@B48]\], 2006                        ^90^Y-DOTATOC then ^177^Lu-DOTATOC                                                                                                       NA                                                                                                                                           Prospective study                                                          20                      Excluding pt (no 3) with Paraganglioma-neck                                  19                                                        30                                                                                                                                                                                                                                 53.8                                                                                                                                    Median            NR                    NR             NR                                                                                                                                                                                                                              Advanced, progressive, and metastatic
  Arnold et al\[[@B31]\], 2005                          Octreotide plus interferon alpha                                                                                                         Octreotide monotherapy                                                                                                                       Clinical trial (RCT), open                                                 114                     Octreotide monotherapy                                                       51                                                        47.1                                                                                                                                                                                                                               58                                                                                                                                      Median            NR                    NR             Octreotide: Functioning (*n* = 23), non-functioning (*n* = 28). Octreotide plus Interferon-alpha: functioning (*n* = 24), non-functioning (*n* = 30)                                                                            Metastatic or locally advanced disease without curative therapeutic option
  Octreotide plus interferon alpha                      54                                                                                                                                       44.4                                                                                                                                         57                                                                         Median                  NR                                                                           NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Nonrandomised                                         9                                                                                                                                        33.3                                                                                                                                         60                                                                         Median                  NR                                                                           NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Teunissen et al\[[@B62]\], 2004                       ^177^Lu-DOTATOC                                                                                                                          None                                                                                                                                         Clinical trial                                                             50                      None                                                                         NA                                                        56.0                                                                                                                                                                                                                               58.3                                                                                                                                    Mean              NR                    26.0           NR                                                                                                                                                                                                                              Metastatic
  Pasieka et al\[[@B43]\], 2004                         I-MIBG                                                                                                                                   NA                                                                                                                                           Clinical trial, open                                                       19                      I-MIBG                                                                       10                                                        40                                                                                                                                                                                                                                 59                                                                                                                                      Mean              90                    10             NR                                                                                                                                                                                                                              Progressive
  Octreotide                                            9                                                                                                                                        55.6                                                                                                                                         55.6                                                                       Mean                    66.6                                                                         33.3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Kwekkeboom et al\[[@B60]\], 2003                      Somatostatin analogue ^177^Lu-DOTATOC                                                                                                    NA                                                                                                                                           Clinical trial, open                                                       35                      None                                                                         NA                                                        60                                                                                                                                                                                                                                 54                                                                                                                                      Mean              NR                    NR             NR                                                                                                                                                                                                                              Metastatic
  Larsson et al\[[@B25]\], 2001                         Interferon, somatostatin analogue, interferon, and a somatostatin                                                                        None                                                                                                                                         Prospective study                                                          24                      None                                                                         NA                                                        42.0                                                                                                                                                                                                                               62.0                                                                                                                                    Median            100                   NR             NR                                                                                                                                                                                                                              NR
  O\'Toole et al\[[@B32]\], 2000                        Octreotide followed by lanreotide                                                                                                        Lanreotide followed by octreotide                                                                                                            Clinical trial (RTC), double blind                                         33                      Patients received octreotide followed by Lanreotide                          16                                                        50                                                                                                                                                                                                                                 63                                                                                                                                      NR                62.5                  0                                                                                                                                                                                                                                              
  Patients received lanreotide followed by octreotide   17                                                                                                                                       53                                                                                                                                           64                                                                         NR                      76                                                                           5.9                                                       NR                                                                                                                                                                                                                                 NR                                                                                                                                                                                                                                                                                                                                                                                                                             
  Wymenga et al\[[@B57]\], 1999                         Lanreotide prolonged release                                                                                                             NA                                                                                                                                           Clinical trial, phase II, open                                             55                      NA                                                                           NA                                                        49.1                                                                                                                                                                                                                               59.7                                                                                                                                    Mean              NR                    5.5            NR                                                                                                                                                                                                                              Advanced (Stage IV), metastatic. Metastatic disease sites: Lymph nodes (*n* = 39), distant organs (*n* = 44)
  Larsson et al\[[@B26]\], 1999                         Ongoing treatment: interferon and octreotide, other                                                                                      NA                                                                                                                                           Cross-sectional                                                            119                     Patients with carcinoid tumours                                              64                                                        43.7                                                                                                                                                                                                                               64                                                                                                                                      Median            53.8                  NA             NR                                                                                                                                                                                                                              NR
  Patients with EPT                                     55                                                                                                                                       37.5                                                                                                                                         54                                                                         Median                  NR                                                                           46.20                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Overall                                               119                                                                                                                                      43.7                                                                                                                                         61                                                                         Median                  53.8                                                                         46.20                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Larsson et al\[[@B38]\] , 1999                        Interferon and/or a somatostatin analogue                                                                                                NA                                                                                                                                           Clinical trial                                                             99                      NA                                                                           NA                                                        39.4                                                                                                                                                                                                                               59                                                                                                                                      Mean              NR                    NR             NR                                                                                                                                                                                                                              Stage = not terminal, no other status provided.
  HADS Anxiety (cases)                                  19                                                                                                                                       NR                                                                                                                                           NR                                                                         NR                      NR                                                                           NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  HADS Depression (cases)                               13                                                                                                                                       NR                                                                                                                                           NR                                                                         NR                      NR                                                                           NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Larsson et al\[[@B69]\], 1998                         Interferon and/or a somatostatin analogue                                                                                                NA                                                                                                                                           Cross-sectional                                                            17                      NA                                                                           NA                                                        47                                                                                                                                                                                                                                 58                                                                                                                                      Mean              NR                    NR             NR                                                                                                                                                                                                                              NR

Disease description provided in each reference. NA: Not available; P-NET: Pancreas-neuroendocrine tumours; CS: Carcinoid syndrome; NR: Not relevant; HADS: Hospital Anxiety and Depression Scale; PRRT: Peptide receptor radionuclide therapy.

![PRISMA diagram of included and excluded studies; the number of studies propagating to each stage of the process are included.](WJG-26-3686-g001){#F1}

Of the total studies, 14 included somatostatin analogues as the intervention, including octreotide (*n* = 7), lanreotide (*n* = 3), pasireotide (*n* = 1), and undefined (*n* = 3). Such treatments slow down the production of hormones, such as serotonin, and thus reduce the symptoms of CS. In two studies, somatostatin analogues were combined with immunotherapy drugs such as interferon\[[@B25],[@B26]\]. Three studies compared somatostatin analogues with placebos, allocated within the context of a randomised controlled trial\[[@B16],[@B27],[@B28]\]. Five studies used somatostatin analogues as comparators for an alternative somatostatin therapy, ^177^Lu-DOTATATE or octreotide combined with interferon alpha\[[@B17],[@B29]-[@B32]\].

In PRRT, a radioactive substance can be combined with a relevant peptide (or its analogue), such as somatostatin, so that it preferentially binds with a high affinity to the tumour. Nine studies considered PRRT as the intervention: ^225^Ac-DOTATATE (*n* = 1), ^177^Lu-DOTATATE (*n* = 5), ^90^Y-DOTATOC (*n* = 2) and/or ^177^Lu-DOTATOC (*n* = 3) (Table [1](#T1){ref-type="table"}). ^177^Lu-DOTATATE was compared with octreotide administered at a high dose in one prospective study\[[@B17]\]. One retrospective study considered PRRT as the comparator\[[@B33]\], with somatostatin analogues or interferon therapy as the intervention.

Everolimus, sunitinib and erythropoietin were studied as interventions in three, three and one studies, respectively. Two studies compared sunitinib with a placebo within the context of randomised control trials\[[@B34],[@B35]\]. Sunitinib was investigated as a comparator of everolimus in an additional study\[[@B36]\]. In some studies, interferon was used within the populations\[[@B25],[@B31],[@B33],[@B37],[@B38]\], but this was not applied to a specific subgroup.

Six studies used chemotherapy as the intervention: These combined bevacizumab with 5-FU/streptozocin (*n* = 2), capecitabine and streptozocin plus cisplatin (*n* = 1), and bevacizumab plus capecitabine (*n* = 1). Two studies followed patients with various ongoing treatments\[[@B37],[@B39]\]. Three studies used chemotherapy treatments as the comparators to chemotherapeutic interventions; two studies combined capecitabine with the anti-angiogenic drug bevacizumab and used the same population data\[[@B40],[@B41]\], whilst one study combined capecitabine and streptozocin as the comparator\[[@B42]\].

Two additional studies identified within the scope of this review focused on meta-iodobenzylguanidine (MIBG) therapy and telotristat ethyl\[[@B43],[@B44]\], respectively. MIBG is a radiometabolic therapy with limited antitumor effect on GEP-NETs. Telotristat ethyl is used to inhibit L-tryptophan hydroxylases TPH-1 and TPH-2 and reduce the production of serotonin, thereby alleviating CS symptoms\[[@B44]\]; this was assessed in the context of a randomised controlled trial, randomised 1:1:1 to receive 250 mg TID, 500 mg TID, and placebo.

HRQoL assessment
----------------

In total, 30 studies employed a version of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ), in which linear transformation is used to standardise the raw score, so that scores range from 0 to 100. The majority of these studies utilised the EORTC QLQ-C30 HRQoL measure (*n* = 28). One study developed a disease-specific quality of life score questionnaire for patients with GI-NETs to supplement EORTC QLQ-C30. Six studies employed the GI-NET specific module QLQ-GI.NET21, of which one study apparently did not use the HRQoL measure in conjunction with EORTC QLQ-C30\[[@B8]\], thus will not show valid data. Others administered the EQ-5D or EQ-VAS to assess patient utilities and/or the Hospital Anxiety and Depression Scale (HADS) (Although HADS is not strictly a HRQoL measure, it provides insight into the anxiety and depressive symptoms of GEP-NET patients' underlying HRQoL) in addition to the EORTC measures (*n* = 5)\[[@B45]\]. Larsson et al\[[@B25]\] reported mean baseline HADS anxiety and depression scores of 4.6 (SD: 4.0) and 3.2 (SD: 2.7), respectively. Four studies applied the Short Form-36 (SF-36) questionnaire\[[@B9],[@B46]-[@B48]\], three of which were cross-sectional studies. Other measures used include the SF-12\[[@B49]\], the Functional Assessment of Cancer Therapy-Anaemia\[[@B50]\] and the Functional Assessment of Chronic Illness Therapy-Diarrhoea (FACIT-D). Pezzilli et al\[[@B49]\] reported no significant difference between P-NET patients and a sample of age- and sex-matched subjects in terms of physical domain (44.7 ± 11.0 *vs* 46.1 ± 9.9, *P* = 0.610), but a significantly lower mental score in the same patients compared to the normative population (42.4 ± 13.0 *vs* 48.2 ± 9.8, *P* = 0.036).

The average HRQoL global health score at baseline and at different timepoints during each trial, obtained by asking patients to rate their overall health, have been reported for the EORTC QLQ-C30 (Table [2](#T2){ref-type="table"}). A higher score represents a higher ("better") level of functioning, including the global health score. This particular tool became the primary focus of this manuscript, as EORTC QLQ-C30 was the single most commonly cited HRQoL dimension (*n* = 24), with global health score providing a single HRQoL dimension for comparison between studies. The average value for the baseline global health score had a range of 56--70. A higher score for symptoms represents a "worse" level of symptoms. Lowest average score ranges were observed for baseline EORTC QLQ-C30 scores in the following symptoms: nausea and vomiting (4.1--20), insomnia (11.0--38.6), appetite loss (9.2--27.8), constipation (0--24.4) and financial difficulties (6--23.6). Diarrhoea demonstrated a wide range of mean values (16.7--78.3), which can be attributed to the heterogeneity of disease symptoms in GI-NET and P-NET patients, indicating that diarrhoea in GEP-NET patients is multifactorial and very variable. Considering disease location, the average baseline global health scores were comparable, ranging from 56--68 for GI-NETs (4 studies) and 56--67 for P-NETs (5 studies).

###### 

Literature reporting scores for health-related quality of life average global health score for gastroenteropancreatic neuroendocrine tumours patients using European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30

  **Ref**.                                                      **Intervention/comparator**                                                                                                                                                    **Time point**                                                       **Global health score**                                                                                                                   **Statistical analysis and *P* values, as presented in the literature**
  ------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------
  Arnold et al\[[@B31]\], 2005                                  Octreotide plus interferon alpha                                                                                                                                               Baseline                                                             57.9                                                                                                                                      0.04 (between treatment arms at 3 mo)
  3 mo                                                          51.2                                                                                                                                                                                                                                                                                                                                                                                          
  Octreotide monotherapy                                        Baseline                                                                                                                                                                       63                                                                                                                                                                                                             
  3 mo                                                          74.4                                                                                                                                                                                                                                                                                                                                                                                          
  Cella et al\[[@B44]\], 2018                                   Telotristat ethyl                                                                                                                                                              \-                                                                   Overall: 55.4; Durable responders: 40; Non-durable responders: 66                                                                         NR (NS)
  Fröjd et al\[[@B37]\], 2007                                   Various (*i.e*. interferon, octreotide, chemotherapy and other)                                                                                                                Timepoint 1                                                          58                                                                                                                                        NR
  Timepoint 2                                                   61                                                                                                                                                                             NR                                                                                                                                                                                                             
  Timepoint 3                                                   58                                                                                                                                                                             NR                                                                                                                                                                                                             
  Timepoint 4                                                   58                                                                                                                                                                             NR                                                                                                                                                                                                             
  van der Horst-Schrivers et al\[[@B67]\], 2009                 NA                                                                                                                                                                             \-                                                                   61.8                                                                                                                                      NR
  Korse et al\[[@B30]\], 2009                                   Long-acting sandostatin LAR                                                                                                                                                    Baseline                                                             70                                                                                                                                        0.275 (repeated measurement analysis using mixed linear models)
  3 mo                                                          71                                                                                                                                                                                                                                                                                                                                                                                            
  6 mo                                                          67                                                                                                                                                                                                                                                                                                                                                                                            
  9 mo                                                          68                                                                                                                                                                                                                                                                                                                                                                                            
  12 mo                                                         64                                                                                                                                                                                                                                                                                                                                                                                            
  Larsson et al\[[@B50]\], 2008                                 Erythropoietin                                                                                                                                                                 Baseline                                                             56                                                                                                                                        NR (NS)
  4 mo                                                          55                                                                                                                                                                                                                                                                                                                                                                                            
  8 mo                                                          66                                                                                                                                                                                                                                                                                                                                                                                            
  2 yr                                                          70                                                                                                                                                                                                                                                                                                                                                                                            
  Larsson et al\[[@B25]\], 2001                                 Interferon, somatostatin analogue, interferon, and a somatostatin.                                                                                                             Baseline                                                             68                                                                                                                                        NR (NS)
  3 mo                                                          59                                                                                                                                                                                                                                                                                                                                                                                            
  6 mo                                                          58                                                                                                                                                                                                                                                                                                                                                                                            
  9 mo                                                          50                                                                                                                                                                                                                                                                                                                                                                                            
  12 mo                                                         63                                                                                                                                                                                                                                                                                                                                                                                            
  Larsson et al\[[@B26]\], 1999                                 Interferon and/or a somatostatin analogue for at least 4 weeks - Five patients were treated with interferon, three with a somatostatin analogue, and nine with a combination   \-                                                                   64.71                                                                                                                                     NR
  Larsson et al\[[@B38]\], 1999                                 Interferon and/or a somatostatin analogue                                                                                                                                      \-                                                                   Overall: 66.7; HADS Anxiety (cases): 46; HADS Anxiety (non-cases): 71.6; HADS Depression (cases): 43; HADS Depression (non-cases): 70.2   \< 0.001 between HADS anxiety "cases" (*n* = 19) and "non-cases" (*n* = 80) and 0.001 between HADS depression "cases" (*n* = 13) and "non-cases" (*n* = 86)
  Larsson et al\[[@B69]\], 1998                                 Interferon and/or a somatostatin analogue and/or a combination                                                                                                                 \-                                                                   64.71                                                                                                                                     NR
  Lewis et al\[[@B3]\], 2018                                    NA                                                                                                                                                                             \-                                                                   Without CS: 63.0; With CS: 61.7                                                                                                           0.04 (between subpopulations)
  Marinova et al\[[@B61]\], 2019                                ^177^Lu-DOTATATE                                                                                                                                                               Baseline                                                             62.6                                                                                                                                      
  3 mo                                                          66.7                                                                                                                                                                           \< 0.05 (compared to baseline using mixed longitudinal model)                                                                                                                                                  
  6 mo                                                          69.6                                                                                                                                                                           \< 0.01 (compared to baseline using mixed longitudinal model)                                                                                                                                                  
  9 mo                                                          69.4                                                                                                                                                                           \< 0.01 (compared to baseline using mixed longitudinal model)                                                                                                                                                  
  Meyer et al\[[@B42]\], 2014                                   Capecitabine and streptozocin plus cisplatin.                                                                                                                                  Baseline                                                             69.3                                                                                                                                      
  ≤ 9 wk - after 3 × 3 weekly cycles                            52.2                                                                                                                                                                           0.052 (compared to baseline)                                                                                                                                                                                   
  6 mo                                                          56                                                                                                                                                                             0.68 (compared to baseline)                                                                                                                                                                                    
  Capecitabine and streptozocin                                 Baseline                                                                                                                                                                       67                                                                                                                                                                                                             
  ≤ 9 wk - after 3 × 3 weekly cycles                            62.2                                                                                                                                                                           0.5 (compared to baseline)                                                                                                                                                                                     
  6 mo                                                          68.9                                                                                                                                                                           0.75 (compared to baseline)                                                                                                                                                                                    
  Mitry et al\[[@B40]\], 2014                                   Bevacizumab plus capecitabine                                                                                                                                                  Baseline                                                             67                                                                                                                                        
  6 mo                                                          63                                                                                                                                                                             NR (NS)                                                                                                                                                                                                        
  12 mo                                                         71                                                                                                                                                                             NR (NS)                                                                                                                                                                                                        
  Pavel et al\[[@B56]\], 2016                                   Everolimus                                                                                                                                                                     End of treatment (compared to baseline)                              P-NET: -3.9; non P-NET: -13                                                                                                               NR
  Ramage et al\[[@B54]\], 2019                                  Everolimus                                                                                                                                                                     1 mo                                                                 FAS Population (paired scores baseline and 1 m): 58                                                                                       NR (NS)
  Continuing tx at 6m (paired scores baseline and 1 m): 56.9    NR (NS)                                                                                                                                                                                                                                                                                                                                                                                       
  2 mo                                                          FAS Population (paired scores baseline and 2 m): 57.6                                                                                                                          NR (NS)                                                                                                                                                                                                        
  Continuing tx at 6m (paired scores baseline and 2 m): 56.9    NR (NS)                                                                                                                                                                                                                                                                                                                                                                                       
  3 mo                                                          FAS Population (paired scores baseline and 3 m): 56.7                                                                                                                          NR (NS)                                                                                                                                                                                                        
  Continuing tx at 6m (paired scores baseline and 3 m): 56.3    NR (NS)                                                                                                                                                                                                                                                                                                                                                                                       
  4 mo                                                          FAS Population (paired scores baseline and 4 m): 56                                                                                                                            NR (NS)                                                                                                                                                                                                        
  Continuing tx at 6 m (paired scores baseline and 4 m): 56.8   NR (NS)                                                                                                                                                                                                                                                                                                                                                                                       
  5 mo                                                          FAS Population (paired scores baseline and 5 m): 56.6                                                                                                                          NR (NS)                                                                                                                                                                                                        
  Continuing tx at 6 m (paired scores baseline and 5 m): 58.6   NR (NS)                                                                                                                                                                                                                                                                                                                                                                                       
  6 mo                                                          FAS Population (paired scores baseline and 6 m): 56.9                                                                                                                          NR (NS)                                                                                                                                                                                                        
  Continuing tx at 6 m (paired scores baseline and 6 m): 56.9   NR (NS)                                                                                                                                                                                                                                                                                                                                                                                       
  Raymond et al\[[@B34]\], 2011                                 Sunitinib                                                                                                                                                                      Baseline                                                             67                                                                                                                                        
  \"post-baseline\"                                             62.4                                                                                                                                                                           NR                                                                                                                                                                                                             
  Placebo                                                       Baseline                                                                                                                                                                       64                                                                                                                                                                                                             
  \"post-baseline\"                                             61.3                                                                                                                                                                           NR                                                                                                                                                                                                             
  Rinke et al\[[@B16]\], 2019                                   Long-acting octreotide                                                                                                                                                         Baseline                                                             64                                                                                                                                        
  Placebo                                                       Baseline                                                                                                                                                                       65.7                                                                                                                                                                                                           
                                                                12 wk                                                                                                                                                                          +4.13 (difference in global health score compared to placebo)        NR                                                                                                                                        
                                                                24 wk                                                                                                                                                                          +5.05 (difference in global health score compared to placebo)        NR                                                                                                                                        
                                                                36 wk                                                                                                                                                                          +1.85 (difference in global health score compared to placebo)        NR                                                                                                                                        
  Strosberg et al\[[@B17]\], 2018                               ^177^Lu-DOTATATE                                                                                                                                                               Baseline                                                             67                                                                                                                                        NR
  High-dose octreotide                                          Baseline                                                                                                                                                                       64                                                                   NR                                                                                                                                        
  Teunissen et al\[[@B62]\], 2004                               ^177^Lu-DOTATOC                                                                                                                                                                Baseline                                                             69                                                                                                                                        
  6 wk                                                          78.2                                                                                                                                                                           \< 0.01 (Analysis of variance (two-sided) compared to baseline)                                                                                                                                                
  Vinik et al\[[@B35]\], 2016                                   Sunitinib                                                                                                                                                                      Baseline                                                             67                                                                                                                                        NR (NS difference between arms)
  Up to cycle 10 (about 9 mo)                                   60.4                                                                                                                                                                                                                                                                                                                                                                                          
  Placebo                                                       Baseline                                                                                                                                                                       64                                                                   NR (NS difference between arms)                                                                                                           
  Up to cycle 10 (about 9 mo)                                   61.3                                                                                                                                                                                                                                                                                                                                                                                          
  Wymenga et al\[[@B57]\], 1999                                 Lanreotide prolonged release                                                                                                                                                   Baseline                                                             60.4                                                                                                                                      
  1 mo                                                          69.7                                                                                                                                                                           0.001 (compared to baseline using t tests or Wilcoxon signed rank)                                                                                                                                             
  End of treatment                                              65.5                                                                                                                                                                           NR (NS)                                                                                                                                                                                                        
  Yadegarfar et al\[[@B33]\], 2013                              Somatostatin analogues or interferon therapy                                                                                                                                   Baseline                                                             61                                                                                                                                        
  3 mo                                                          67                                                                                                                                                                             NR                                                                                                                                                                                                             
  6 mo                                                          67                                                                                                                                                                             NR                                                                                                                                                                                                             
  Zandee et al\[[@B58]\], 2019                                  ^177^Lu-DOTATATE                                                                                                                                                               Baseline                                                             61.7                                                                                                                                      
  3 mo (after final PRRT cycle)                                 79.5                                                                                                                                                                           0.002 (compared to baseline using paired *t* test)                                                                                                                                                             

NA: Not available; NET: Neuroendocrine tumours; CS: Carcinoid syndrome; NR: Not relevant; PRRT: Peptide receptor radionuclide therapy; NS: Not significant.

Whilst the most popular HRQoL measure was EORTC QLQ-C30, studies that employed the QLQ-GI.NET21 module provided domain scores specific to the disease that is the focus of this report, including: endocrine systems, gastrointestinal systems, disease-related worries, bone/muscle pain *etc*. Table [3](#T3){ref-type="table"} presents the scores given for these domains. The average HRQoL score ranges for body image (13.3--29.1), weight gain (9-27.8) information/communication (1.1--16.0) and treatment-related symptoms (6.5--26.24) showed that these were only minor problems experienced by patients with GI-NETS. Other domains displayed a wide range of scores, *e.g*. sexual function (28.2--68.4), social function (30.0--72.9) and disease-related worries (37.6--84.2), making these some of the most important problems experienced by many patients. The QLQ-GI.NET21 module has been validated as a responsive tool for assessing HRQoL of patients with GEP-NETs\[[@B33]\], although it is accepted that numbers were too small for a proper validation in patients with P-NETs alone. This is of relevance, as P-NET patients often present with a more aggressive disease and concomitant treatments may be used.

###### 

The specific domain scores reported in the literature for gastroenteropancreatic neuroendocrine tumours patients using QLQ-GI.NET21

  **Ref**.                                                    **Intervention/ comparator**         **Time point**                           **Endocrine Symptoms**   **Gastrointestinal Symptoms**   **Social function**   **Disease related worries**   **Muscle/bone pain symptom**   **Weight gain**   **Information/Communication function**   **Body Image**   **Sexual function**   **Treatment related symptoms scale**
  ----------------------------------------------------------- ------------------------------------ ---------------------------------------- ------------------------ ------------------------------- --------------------- ----------------------------- ------------------------------ ----------------- ---------------------------------------- ---------------- --------------------- --------------------------------------
  Ramage et al\[[@B54]\], 2019                                Everolimus                           Baseline (paired scores with 3 mo)       14.8                     24.4                            44.1                  51.1                          35.2                           NR                1.9                                      25.9             37                    NA
                                                              3 mo                                 12.3                                     20.2                     42.6                            44.8                  35.2                          NR                             4.6               24.1                                     42.6             22                    
                                                              Baseline (paired scores with 6 mo)   14.4                                     25.8                     44.8                            50.9                  33.3                          NR                             1.1               20                                       35.6             NA                    
                                                              6 mo                                 12.6                                     21.8                     34.4                            43.7                  30                            NR                             1.1               21.1                                     37.8             14.1                  
  Lewis et al\[[@B3]\], 2018                                  NA                                   Single timepoint (patients without CS)   16.7                     18.9                            60.0                  56.9                          41.3                           18.7              10.7                                     15.3             60.8                  17.5
                                                                                                   Single timepoint (patients with CS)      28.4                     24.0                            68.4                  38.7                          46.7                           13.3              16.0                                     13.3             68.4                  10.1
  Yadegarfar et al\[[@B33]\], 2013                            Various                              Baseline (P-NETs)                        22                       26                              39                    56                            25                             11                10                                       25               32                    18
                                                                                                   3 mo (P-NETs)                            16                       18                              33                    44                            31                             9                 4                                        21               31                    22
                                                                                                   6 mo (P-NETs)                            18                       22                              30                    50                            32                             13                10                                       19               31                    23
  Ballal et al\[[@B8]\], 2019                                 ^225^Ac-DOTATATE TAT                 Baseline                                 21.4                     40.2                            64.3                  61.2                          38.8                           25                NR                                       28.8             40                    6.53
                                                                                                   End of assessment                        3.57                     22.8                            72.9                  84.2                          26.8                           27.8              NR                                       15.6             45                    26.24
  Strosberg et al\[[@B17]\], 2018                             ^177^Lu-DOTATATE                     Baseline                                 NR                       22.8                            33.4                  43.7                          29                             NR                5.4                                      20               30.6                  11.6
                                                              High-dose octreotide                 Baseline                                 NR                       23.8                            37.1                  43.8                          34.6                           NR                12.3                                     20.3             28.2                  11.9
  Cella et al\[[@B44]\], 2018                                 Telotristat ethyl                    Baseline (Durable responders)            37.8                     33.8                            46.7                  41.1                          35                             NR                5                                        29.1             47.2                  18.1
  Baseline (Nondurable responders)                            29.5                                 28.5                                     38.5                     37.6                            30.3                  NR                            7                              26.9              32.6                                     12.8                                   
  Difference in change from baseline between subpopulations   -1.9                                 -9.6                                     -2.8                     1.9                             -4.5                  NR                            3.9                            1                 -1.6                                     -3.4                                   

NA: Not available; P-NET: Pancreas-neuroendocrine tumours; CS: Carcinoid syndrome; NR: Not relevant.

In addition, a 10-point change in an EORTC domain score is frequently considered a minimal clinically important difference and, using Kaplan-Meier methodology, time to deterioration (TTD) can be measured using a 10-point decline in analogy with time to event curves\[[@B51],[@B52]\]. Two studies identified in the literature search applied the use of minimal important difference in the change in HRQoL domains as a means of assessing the impact of interventions using TTD, and time until definitive deterioration (TUDD), *i.e*. ≥ 10 point worsening of a HRQoL domain score from baseline without further improvement\[[@B16],[@B17]\].

The SF-36 measures eight dimensions of HRQoL, where item scores are linearly transformed into scales ranging from 0 to 100, with higher scores indicating better HRQoL. In cross-sectional studies, HRQoL has been shown to be significantly reduced in patients with GEP-NETs compared to the general population in every SF-36 dimension\[[@B46],[@B47]\]: 77.9 *vs* 70.0 for physical functioning, 65.0 *vs* 40.2 for role physical, 69.1 *vs* 64.3 for bodily pain, 74.3 *vs* 54.8 for general health, 60.9 *vs* 49.5 for vitality, 83.9 *vs* 75.5 for social functioning, 77.4 *vs* 64.4 for role emotional and 80.6 *vs* 74.9 for mental health. Mean scores for each scale were consistently worse in a sub-population of patients with impaired bowel/bladder function, which was strongly correlated with high scores for diarrhoea\[[@B46]\], a symptom of CS which reduces patient HRQoL. Elsewhere, Haugland et al\[[@B9]\] reported only the physical component (39.6) and the mental component (45.9) scores; these were similar to baseline scores previously reported\[[@B53]\]. Frilling et al\[[@B48]\] reported improved HRQoL (assessed using SF-36) in 50% of patients in their prospective study of ^90^Y-DOTATOC therapy followed by ^177^Lu-DOTATOC, but sample size was low (*n* = 20).

Various studies used other HRQoL tools to evaluate HRQoL in GEP-NET patients; direct comparisons between these studies were limited by the small number of studies using each tool (*n* ≤ 2) and the heterogenous population and treatment interventions. Pezzilli et al\[[@B49]\] was the only identified publication to use SF-12 in a population of P-NET patients, reporting a good physical HRQoL that was not significantly different to the normative population (44.7 ± 11.0 *vs* 46.1 ± 9.9, *P* = 0.610), but a significantly impaired mental component (42.4 ± 13.0 *vs* 48.2 ± 9.8, *P* = 0.036). Pezzilli et al\[[@B49]\] was also the only study to employ the Beck Depression Inventory and State Anxiety Inventory Y-1; 8 patients (18.2%) identified with moderate depression, 9 patients (20.5%) with mild moderate depression, and 27 patients (61.4%) with no depression. Anxiety results were similar in the patients and in the normative population. Ramage et al\[[@B54]\] used the EQ-5D-5L (in addition to EORTC QLQ-C30 and GINET21), with no significant difference for the composite health index or self-rated (global) health score noted between baseline and 6-mo treatment with everolimus. The EQ-5D VAS was employed in two studies: Kulke et al\[[@B55]\] examined patients receiving repeated 6-weekly cycles of oral sunitinib, noting no significant difference in VAS scores over the study period, whilst Pavel et al\[[@B56]\] reported a reduced mean VAS from baseline to end of treatment with oral everolimus (10 mg daily, in 28-d cycles) in non-P-NET patients (63.9 ± 19.0 *vs* 55.3 ± 23.0, respectively) compared to P-NET patients (68.8 ± 19.9 *vs* 66.5 ± 20.6, respectively). The FACIT-D measure is a symptom-specific measure used by Kvols et al\[[@B29]\] in a Phase II, open-label, multicentre prospective study of self-administered pasireotide. Clinical responders were noted to have improved mean scores at the end of treatment compared to baseline. Kulke et al\[[@B55]\] reported that the mean FACIT-fatigue score remained stable for each treatment cycle of sunitinib with a "modest" score increase during the dosing period. Elsewhere, Larsson et al\[[@B50]\] used the Functional Assessment of Cancer Therapy-Anaemia measure to assess the HRQoL of GEP-NET patients with anaemia being treated with erythropoietin; no significant changes were observed over the study period. Finally, O'Toole et al\[[@B32]\] showed no significant difference in HRQoL scores between lanreotide and octreotide using the Index de Santé Perceptuel de Nottingham measure. These studies provide a basis for future randomised control trials to test whether interventions improve HRQoL for patients with GEP-NETs.

All studies included in this review reported the HRQoL of patients with inoperable tumours; the majority of which described the disease as metastatic and/or advanced (Table [1](#T1){ref-type="table"}), and thus the disease could be categorised as stage IV. Out of these studies, only two provided explicit information regarding disease stage for the entire study population\[[@B57],[@B58]\]. Notably, no studies investigated how disease stage and tumour functionality affect HRQoL in GEP-NET patients, with HRQoL data most often presented according to treatment comparator.

Treatment impact on HRQoL
-------------------------

Few studies reported a significant difference (*P* \< 0.05) in the patients' global health score between baseline and after a period of treatment (Table [2](#T2){ref-type="table"}).

HRQoL was maintained with few deteriorations in patients receiving long-acting octreotide compared to the deterioration observed in patients who received a placebo\[[@B16],[@B27]\]. Octreotide improved HRQoL scores for the clinically important GEP-NET symptoms such as fatigue, insomnia, diarrhoea and pain; whereas significantly earlier TUDD was observed in the placebo arm for fatigue, pain and insomnia in patients with GI-NETs than those treated with long-acting octreotide (*P* \< 0.05)\[[@B16]\]. An improvement in the EORTC global health score was shown after 3 mo on octreotide but not when octreotide was combined with interferon alpha\[[@B31]\]. Flushing was shown to be reduced significantly following 12 mo of treatment with long-acting octreotide\[[@B30]\]. Further studies are deemed necessary to assess the HRQoL of GEP-NET patients treated with pasireotide, who are refractory or resistant to octreotide; symptom-specific scores and total FACIT-D assessments showed some variability and no clear trends but sample size was small (*n* = 30)\[[@B29]\].

Another somatostatin analogue shown to bring about significant improvement in the global health score of GEP-NET patients was prolonged-release lanreotide\[[@B57]\], possibly driven by improvements in symptom scales or single-term measures such as fatigue, pain, nausea/vomiting, sleeping problems, appetite, constipation, diarrhoea and financial problems; although dyspnoea became more severe during the 6-mo treatment period. O'Toole et al\[[@B32]\] found no significant HRQoL differences between lanreotide and octreotide, although most patients prefer lanreotide due to its simplified mode of administration. However, examining evidence from the CLARINET study, and mapping EORTC QLQ-C30 to EQ-5D-based utility values, no significant differences in HRQoL were noted between the lanreotide and placebo arms\[[@B28]\].

PRRT treatment for GEP-NETs has been shown to result in stable HRQoL scores during and after a 3-mo treatment period, compared to baseline levels using the EORTC QLQ-C30 measure\[[@B59],[@B60]\]. In more recent studies, treatment with ^177^Lu-DOTATATE was shown to be a safe and effective therapy in the treatment of functioning P-NETs\[[@B58]\] leading to a significant increase in the global health score observed at follow-up compared to baseline (79.5 *vs* 61.7, *P* = 0.002). Furthermore, significant improvements in the physical functioning, role functioning, emotional functioning, and social functioning were reported. Of all symptom scales, only "fatigue" was found to have significantly decreased (27.3 *vs* 17.2, *P* = 0.02). These results are consistent with a recent retrospective analysis study conducted by Marinova\[[@B61]\]; HRQoL was significantly improved in GI-NET patients receiving ^177^Lu-DOTATATE compared to baseline, revealing an increased global health score (3 mo after 1^st^, 2^nd^, and 3^rd^ treatment cycle *P* = 0.049, *P* = 0.004, and *P* = 0.041, respectively).

In the Phase III NETTER-1 study, 231 patients were recruited with 117 randomised to the ^177^Lu-DOTATATE arm (200 mCi every 8 wk for four treatments) and 114 to the high-dose octreotide long-acting repeatable arm (60 mg every 4 wk)\[[@B17]\]. HRQoL analysis, conducted on an intention-to-treat basis, demonstrated that ^177^Lu-DOTATATE provides a significant and clinically robust HRQoL benefit for patients with progressive GI-NETs (compared to high-dose octreotide). TTD, defined as the time from randomisation to first HRQoL deterioration of ≥ 10 points from baseline score, was significantly longer in the ^177^Lu-DOTATATE arm (*P* \< 0.001); the hazard ratio was 0.406 for global health status, 0.518 for physical functioning, 0.580 for role functioning, 0.621 for fatigue, 0.566 for pain, 0.473 for diarrhoea, 0.425 for body image and 0.572 for disease-related worries. Differences in median TTD were clinically significant in several domains: 28.8 mo *vs* 6.1 mo for global health status, and 25.2 mo *vs* 11.5 mo for physical functioning. Significant improvements in TUDD were also observed for the global health score (*P* \< 0.001), as well as for physical functioning (*P* = 0.002), role functioning (*P* \< 0.001), emotional functioning (*P* = 0.020), social functioning (*P* = 0.001), pain (*P* = 0.002), insomnia (*P* = 0.026), appetite loss (*P* = 0.009), constipation (*P* = 0.042), diarrhoea (*P* = 0.001), GI scale (*P* = 0.005), treatment scale (*P* = 0.002), social function scale (*P* = 0.011), disease-related worries scale (*P* = 0.001), and body image (*P* = 0.002).

Other PRRT interventions included the use of ^177^Lu-DOTATOC\[[@B62]\], ^90^Y-DOTATOC\[[@B59]\] and ^225^Ac-DOTATATE\[[@B8]\]. ^177^Lu-DOTATOC treatment improved functional scales and most single item scores in GEP-NET patients, whilst symptom scale scores for fatigue and pain decreased significantly from 31.9 to 22.8 (*P \<* 0.01) and 23.3 to 15.0 (*P \<* 0.05), respectively\[[@B62]\]. Martini et al\[[@B59]\] examined HRQoL following 4--6 cycles of ^177^Lu-DOTATATE or ^90^Y-DOTATOC. The most significant domain change for GI-NETs was noted for diarrhoea (-16.3 points, *P* = 0.008). Compared to ^90^Y-DOTATOC, ^177^Lu-DOTATATE demonstrated a reduced score for fatigue (-27.7 points, *P* = 0.020) and better physical functioning (+22.4 points, *P* = 0.050), cognitive functioning (+23.1 points, *P* = 0.003) and global health score (+17.3 points, *P* = 0.029) in P-NET patients. ^225^Ac-DOTATATE therapy has the potential to overcome the resistance of GEP-NET to ^177^Lu-DOTATATE beta therapy and promote remission with minimal or transient toxicity, whilst reducing endocrine (*P* = 0.001) and gastrointestinal symptoms (*P* \< 0.001), although treatment-related symptoms were worsened by the end of the assessment (*P* = 0.001)\[[@B8]\].

A significant difference in the EORTC QLQ-C30 physical functioning scale was noted by Ramage et al\[[@B54]\] following 6-mo treatment with everolimus, but no other significant differences were noted during this treatment period; in line with what was also shown by analysis conducted in conjunction with the RADIANT trial\[[@B56]\]. Likewise, sunitinib has no significant impact on global health score of EORTC QLQ-C30, but it has been shown to improve the HRQoL symptom scores of insomnia and diarrhoea compared to placebo in P-NETs\[[@B34],[@B35]\]. In another study\[[@B55]\], there was no significant difference in EQ-VAS scores over 6 treatment cycles of sunitinib. There was no significant impact on the HRQoL of patients with GI-NETs when treated with erythropoietin for the anaemia associated with interferon therapy\[[@B50]\].

Chemotherapy in the BETTER trial was chosen based on NET location; GI-NETs were treated with capecitabine and bevacizumab, whilst P-NETs patients received 5-fluorouracil/streptozocin with bevacizumab. Differences in the EORTC QLQ-C30 global health score between baseline, 3-mo, 6-mo and 12-mo follow-up assessments were not significant\[[@B40],[@B41]\]. The NET01 trial suggested that the addition of cisplatin to the combined capecitabine and streptozocin regimen worsened HRQoL\[[@B42]\]. After three cycles, the mean global health score was 67.0 *vs* 62.2 (*P* = 0.5) in the capecitabine and streptozocin arm and 69.3 *vs* 52.2 (*P* = 0.052) in the capecitabine and streptozocin plus cisplatin arm. After 6 cycles, mean global health score remained virtually unchanged in the capecitabine and streptozocin arm from 66.7 *vs* 68.9 (*P* = 0.75) and 59.8 *vs* 56.0 (*P* = 0.68) in the capecitabine and streptozocin plus cisplatin arm. All three studies were based on small HRQoL sample sizes (less than 100).

Of the remaining treatments identified within the scope of this study, the HRQoL was improved or remained the same in all GEP-NET patients treated with MIBG therapy. Three studies used more than one treatment in the populations studied without breaking down HRQoL results into treatment categories\[[@B26],[@B37],[@B38]\]. Using HADS, Larsson et al\[[@B25]\] noted a lower anxiety rating at 12 mo (*P* \< 0.05) following treatment with interferon, somatostatin analogue or a combination of both, whilst the depression score was significantly higher at 9 mo (*P* \< 0.01) when compared to baseline. The study by Fröjd et al\[[@B37]\] suggested a slight increase in HADS anxiety over time (timepoints unspecified) in a longitudinal study of octreotide and/or interferon or chemotherapy or no treatment, but sample size was small and significance was not reported. Finally, telotristat ethyl therapy was not shown to be associated with any measurable short-term HRQoL benefits when assessed using the EORTC QLQ-30 measure, beyond diarrhoea\[[@B44]\].

DISCUSSION
==========

Given the indolent nature and slow progression of disease in most GEP-NET patients, assessment of HRQoL is vital for monitoring impact of treatment. The lack of conclusive data on outcomes in GEP-NETs can be attributed, in part, to the small sample size of clinical trials involving GEP-NETs that makes it difficult to capture clinically meaningful changes or a significant benefit in terms of HRQoL\[[@B6]\]. Moreover, the work by Martini et al\[[@B18]\] showed that a transfer of HRQoL results into clinical practice is hindered by the scarcity of robust studies and the quality of HRQoL assessment\[[@B18]\]. To our knowledge, our study is the first to report a systematic review investigating the impact of treatments on the HRQoL of GEP-NET patients and the development status of instruments used in terms of validation and minimal important difference.

Martini et al\[[@B18]\] performed a systematic review examining methodological robustness of HRQoL studies of patients with GEP-NETs. They concluded that heterogeneity and limited methodological quality of considered studies did not permit them to draw conclusions regarding the impact of HRQoL in clinical practice. In agreement, our review confirmed heterogeneity of studies and patient characteristics, including variety in intervention or comparator treatment, disease severity and location of primary tumour, age, gender and other symptoms or comorbidities. Sample size for studies considered eligible for inclusion ranged from 17 to 253 patients, with a median of 57, highlighting the usual small number of study participants. A similar median value of 51 (range 9--663 patients) was reported by Martini et al\[[@B18]\]. Further, where comparator groups were used, HRQoL scores were sometimes reported for the entire study population and not for the respective treatment groups in the study\[[@B29],[@B33],[@B40],[@B41],[@B44]\]. Due to the wide range of comparators identified and the significant heterogeneity across the studies included in this review, which would violate the assumptions of meta-analysis, HRQoL related to various GEP-NET treatments was assessed in a qualitative manner rather than quantitative (*e.g*. meta-analysis).

In line with Martini et al\[[@B18]\], we identified the well-validated EORTC QLQ-C30 as the most commonly used HRQoL instrument in GEP-NET patients. The EORTC instrument has been used in 30 out of 43 published studies; however, validation and definition of minimal important difference have not been reported to date specifically for GEP-NET patients. The EORTC QLQ-GINET21 module (*n* = 6) and the SF-12/36 tools (*n* = 5) have occasionally been used, with other instruments used in two or less publications.

Where change in the EORTC QLQ-C30 global health score could be calculated from baseline scores (Table [2](#T2){ref-type="table"}), six studies demonstrated a trend towards an improved score, three showed a decline, with the remaining studies presenting mixed or inconsistent responses depending on intervention and/or follow-up time point. However, results should be interpreted with caution for the reasons given above. The mixed HRQoL trends are comparable to those reported by Jimenez-Fonseca et al\[[@B63]\], who highlighted the existing evidence for improved treatment efficacy, safety or toxicity for a range of therapies, including somatostatin analogues, sunitinib and everolimus, but with mixed HRQoL response. Jimenez-Fonseca et al\[[@B63]\] suggested the generic EORTC QLQ-C30 has not been developed specifically for GEP-NET patients and, therefore, may lack the sensitivity to detect subtle HRQoL changes in association with disease items that are relevant to GEP-NET patients.

Given the potentially long treatment duration in GEP-NET patients, one challenge of HRQoL analysis is taking the potential occurrence of a response shift into consideration. This can occur as self-assessment of HRQoL is inherently subjective; patients can adapt to their disease and the treatment toxicities resulting in changing standards of HRQoL over time\[[@B51]\]. Thus, the choice of the reference score to qualify a change such as deterioration is a major concern. With this in mind, it is difficult to determine the change in HRQoL over time in most studies identified in this systematic review. One approach that deals with response shift effect as a concept is evaluation of TTD, making use of minimal important difference as a criterion for signalling deterioration. In the Phase III trial NETTER-1, it was shown that adjusting for significant covariates (HRQoL baseline values, OctreoScan maximum tumour uptake score, and/or age), the impact of treatment remained statistically significant for global health score, physical functioning, diarrhoea, and body image domains\[[@B17]\]. Osoba et al\[[@B52]\] rated patients' perceived change in EORTC QLQ-C30 in breast cancer or small-cell lung cancer patients, concluding a "moderate" change equated to a 10--20 change in mean scores. Use of a minimal important difference of at least 10 points as a criterion for deterioration yielded TTD curves with a time course similar to that of the curves for centrally reviewed radiological progression\[[@B17]\]. It should be noted, however, that the "minimal important difference" was not defined specifically for patients with midgut NETs participating in the NETTER-1 study. Moreover, the TTD and TUDD criterion of a drop in ≥ 10 points in a domain score was used to show more than half of the EORTC QLQ-30 domains improved for patients treated with ^177^Lu-DOTATATE compared to a control arm; the same TUDD criterion was also applied by Rinke et al\[[@B16]\], who showed long-acting octreotide significantly extended TUDD for fatigue, pain and insomnia HRQoL domains compared to a placebo.

Treatment of GEP-NETs with ^177^Lu-DOTATATE consistently improved global health score compared to baseline\[[@B58],[@B61],[@B62]\] and increased TTD. The Phase III NETTER-1 study provides the best information available regarding HRQoL in patients with advanced progressive GEP-NETs not only in terms of benefit but also in terms of TTD\[[@B17]\]. However, the minimal important difference (and clinically meaningful thresholds) for improvement/worsening has not been defined yet for the EORTC QLQ-C30 specifically in GEP-NET patients, although it has for a number of other common cancers\[[@B64],[@B65]\]. It is conceivable that the abbreviated version of the EORTC QLQ-C30 (possibly combined with GINET21 and computer adaptive testing) can be developed especially for use in clinical practice. Thus, there is scope for further research in this area and exploration of HRQoL as a potential tool for monitoring disease progression. Longitudinal studies with a long-term follow-up and involving clinical practice patients may provide further insight into the potential role of HRQoL in patient monitoring and management.

In conclusion, study and patient heterogeneity, small sample sizes and limited methodological quality in terms of assessing HRQoL has impaired definitive statements being made regarding the impact of the various treatment options for GEP-NETs in terms of HRQoL\[[@B66]-[@B69]\]. A number of randomised trials demonstrated only small or no HRQoL changes between active treatment and placebo arms. The Phase III NETTER-1 is the only study to have shown more significant and robust differences between active and placebo groups. It demonstrated that PRRT can delay the time to worsening of HRQoL in GEP-NET patients. However, validation of QLQ-C30 and GINET21 specifically for GI-NET and P-NET patients, and definition of minimal important difference and clinical thresholds, are still lacking for these patients. As such, further research is necessary in order to offer a benchmark for interpreting the clinical importance of differences in HRQoL domain scores between groups or changes in these scores over time in conjunction with different treatment modalities.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are slow-growing cancers that arise from diffuse endocrine cells in the gastrointestinal tract (GI-NETs) and pancreas (P-NETs). The majority of patients who are diagnosed with GEP-NETs have metastatic disease. Despite this, systemic therapies provide a 5-year survival rate of about 75% for patients with GI-NETs and \> 60% for patients with P-NETs.

Research motivation
-------------------

Health related quality of life (HRQoL) is an increasingly important concept, reflecting the patients' perspective in conjunction with the disease presentation, severity, and treatment. Although not curative, long-term therapeutic options are available for patients with GEP-NETs to provide symptomatic relief, and these can even slow down and stabilise disease for multiple years. Since patients can live many years by managing their disease in this way, understanding the impact of treatment on GEP-NETs patients' HRQoL is paramount especially given the indolent course the disease may take in patients.

Research objectives
-------------------

The aim of this study was to perform a systematic review to assess the HRQoL of patients with inoperable metastatic GEP-NETs undergoing various treatments in order to uncover areas for future research. This systematic literature review is a response to the increased importanceof assessing HRQoL with validated patient-reported outcome instruments for which the minimal important difference has been defined.

Research methods
----------------

The systematic review performed here adhered to the established international guidelines for conducting systematic reviews. A search strategy was developed and refined to recover relevant publications reporting HRQoL data for adult patients with GEP-NETs. Data were extracted from every record returned by the literature search that met the inclusion criteria of the study.

Research results
----------------

A total of 42 studies met the inclusion criteria of the study. The EORTC QLQ-C30 and gastrointestinal GI-NET module (QLQ-GI.NET21) were the most used HRQoL instruments, exhibiting a range of outcomes compared to baseline for the specific interventions.

The worst HRQoL observed at baseline were related to the following symptoms: Nausea and vomiting (4.1--20.0), insomnia (11.0--38.6), appetite loss (9.2--27.8), constipation (0--24.4) and financial difficulties (6.0--23.6). Diarrhoea demonstrated a wide range of mean values (16.7--78.3), which can be attributed to the heterogeneity of involved GEP-NET patients.

The average value for the baseline global health score had a range of 56--70. Where change in the EORTC QLQ-C30 global health score could be calculated from baseline scores, five studies demonstrated a significant trend towards an improved score. Treatment of GEP-NETs with ^177^Lu-DOTATATE consistently improved global health score compared to baseline and increased time-to-deterioration, *i.e*. time until HRQoL worsens by at least 10 points for each domain (*e.g*. global health, physical functioning). The Phase III NETTER-1 study resulted in time-to-deterioration curves consistent with the curves for progression free survival for ^177^Lu-DOTATATE. However, the EORTC QLQ-C30 and QLQ-GINET21 have not been validated, and the minimal important differences have not yet been defined, specifically for GI-NET and P-NET patients.

Research conclusions
--------------------

Study and patient heterogeneity, small sample sizes and limited methodological quality in terms of assessing HRQoL has impaired definitive statements being made regarding the impact of the various treatment options for GEP-NETs in terms of HRQoL. A notable finding was that PRRT can delay the time to worsening of HRQoL in GEP-NET patients. However, validation of EORTC QLQ-C30 and GINET21 specifically for GI-NET and P-NET patients and the definitions of minimal important difference and clinical thresholds are still lacking for these patients. As such, further research is necessary in order to offer a benchmark for interpreting the clinical importance of differences in HRQoL domain scores between treatment groups or changes in these scores over time in conjunction with different treatment modalities.

Research perspectives
---------------------

Further research is necessary in order to offer a benchmark for interpreting the clinical importance of differences in HRQoL domain scores over time and between treatment groups.
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